{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:11:58Z","timestamp":1789701118663,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T00:00:00Z","timestamp":1185840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s00262-007-0370-8","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T08:15:12Z","timestamp":1185783312000},"page":"233-246","source":"Crossref","is-referenced-by-count":54,"title":["Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein"],"prefix":"10.1007","volume":"57","author":[{"given":"Julia","family":"Stieglmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja M.","family":"Liebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00f6rg","family":"B\u00fchring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuat","family":"Oduncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertold","family":"Emmerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg H.","family":"Fey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,31]]},"reference":[{"key":"370_CR1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1359-6101(03)00029-7","volume":"14","author":"A Almasan","year":"2003","unstructured":"Almasan A, Ashkenazi A (2003) Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337","journal-title":"Cytokine Growth Factor Rev"},{"key":"370_CR2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155","journal-title":"J Clin Invest"},{"key":"370_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/01.cji.0000175684.28615.7b","volume":"29","author":"K Barbin","year":"2006","unstructured":"Barbin K, Stieglmaier J, Saul D, Stieglmaier K, Stockmeyer B, Pfeiffer M, Lang P, Fey GH (2006) Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. J Immunother 29:122","journal-title":"J Immunother"},{"key":"370_CR4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2141.1996.d01-1900.x","volume":"95","author":"W Baum","year":"1996","unstructured":"Baum W, Steininger H, Bair HJ, Becker W, Hansen-Hagge TE, Kressel M, Kremmer E, Kalden JR, Gramatzki M (1996) Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol 95:327","journal-title":"Br J Haematol"},{"key":"370_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0022-1759(96)00227-X","volume":"201","author":"CA Benedict","year":"1997","unstructured":"Benedict CA, MacKrell AJ, Anderson WF (1997) Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 201:223","journal-title":"J Immunol Methods"},{"key":"370_CR6","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1074\/jbc.M601553200","volume":"281","author":"C Bossen","year":"2006","unstructured":"Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281:13964","journal-title":"J Biol Chem"},{"key":"370_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.11702","volume":"109","author":"E Bremer","year":"2004","unstructured":"Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281","journal-title":"Int J Cancer"},{"key":"370_CR8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1593\/neo.04229","volume":"6","author":"E Bremer","year":"2004","unstructured":"Bremer E, Samplonius D, Kroesen BJ, van Genne L, de Leij L, Helfrich W (2004) Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6:636","journal-title":"Neoplasia"},{"key":"370_CR9","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/0008-5472.CAN-04-2756","volume":"65","author":"E Bremer","year":"2005","unstructured":"Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W (2005) Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380","journal-title":"Cancer Res"},{"key":"370_CR10","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1074\/jbc.M413673200","volume":"280","author":"E Bremer","year":"2005","unstructured":"Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280:10025","journal-title":"J Biol Chem"},{"key":"370_CR11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2141.2005.05414.x","volume":"130","author":"J Bruenke","year":"2005","unstructured":"Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130:218","journal-title":"Br J Haematol"},{"key":"370_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.taap.2004.03.021","volume":"199","author":"J Bustamante","year":"2004","unstructured":"Bustamante J, Caldas Lopes E, Garcia M, Di Libero E, Alvarez E, Hajos SE (2004) Disruption of mitochondrial membrane potential during apoptosis induced by PSC 833 and CsA in multidrug-resistant lymphoid leukemia. Toxicol Appl Pharmacol 199:44","journal-title":"Toxicol Appl Pharmacol"},{"key":"370_CR13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.01.024","volume":"33","author":"BD Cheson","year":"2006","unstructured":"Cheson BD (2006) Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 33:S2","journal-title":"Semin Oncol"},{"key":"370_CR14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2141.2000.02404.x","volume":"111","author":"K Clodi","year":"2000","unstructured":"Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A (2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580","journal-title":"Br J Haematol"},{"key":"370_CR15","first-page":"662","volume":"8","author":"MI Cockett","year":"1990","unstructured":"Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (N Y) 8:662","journal-title":"Biotechnology (N Y)"},{"key":"370_CR16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","volume":"7","author":"MA Degli-Esposti","year":"1997","unstructured":"Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813","journal-title":"Immunity"},{"key":"370_CR17","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910","journal-title":"N Engl J Med"},{"key":"370_CR18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","volume":"83","author":"MA Ghetie","year":"1994","unstructured":"Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83:1329","journal-title":"Blood"},{"key":"370_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1994.tb04726.x","volume":"86","author":"J Greil","year":"1994","unstructured":"Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U, Hansen-Hagge TE, Bartram CR, Fey GH, Stehr K et al (1994) The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 86:275","journal-title":"Br J Haematol"},{"key":"370_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(99)00220-3","volume":"237","author":"W Helfrich","year":"2000","unstructured":"Helfrich W, Haisma HJ, Magdolen V, Luther T, Bom VJ, Westra J, van der Hoeven R, Kroesen BJ, Molema G, de Leij L (2000) A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions. J Immunol Methods 237:131","journal-title":"J Immunol Methods"},{"key":"370_CR21","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ, Szczepanski T (2002) Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 162","DOI":"10.1182\/asheducation-2002.1.162"},{"key":"370_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-5876-3-22","volume":"3","author":"BL Hylander","year":"2005","unstructured":"Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA (2005) The anti-tumor effect of Apo2L\/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22","journal-title":"J Transl Med"},{"issue":"Suppl 2","key":"370_CR23","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","volume":"11","author":"S Inoue","year":"2004","unstructured":"Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193","journal-title":"Cell Death Differ"},{"key":"370_CR24","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/sj.cdd.4401977","volume":"13","author":"S Inoue","year":"2006","unstructured":"Inoue S, Twiddy D, Dyer MJ, Cohen GM (2006) Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 13:2160","journal-title":"Cell Death Differ"},{"key":"370_CR25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V91.3.1001","volume":"91","author":"C Ito","year":"1998","unstructured":"Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Campana D (1998) Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91:1001","journal-title":"Blood"},{"key":"370_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","volume":"26","author":"R Kawagoe","year":"2002","unstructured":"Kawagoe R, Kawagoe H, Sano K (2002) Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26:495","journal-title":"Leuk Res"},{"key":"370_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31","journal-title":"J Pharmacol Exp Ther"},{"key":"370_CR28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","volume":"119","author":"GA Kennedy","year":"2002","unstructured":"Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D (2002) Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin\u2019s lymphoma: a retrospective review. Br J Haematol 119:412","journal-title":"Br J Haematol"},{"key":"370_CR29","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2003-05-1735","volume":"103","author":"P Lang","year":"2004","unstructured":"Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ, Pfeiffer M, Handgretinger R, Niethammer D, Fey GH (2004) Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 103:3982","journal-title":"Blood"},{"key":"370_CR30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.leu.2402251","volume":"15","author":"LF Lincz","year":"2001","unstructured":"Lincz LF, Yeh TX, Spencer A (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15:1650","journal-title":"Leukemia"},{"key":"370_CR31","doi-asserted-by":"crossref","first-page":"25417","DOI":"10.1074\/jbc.272.41.25417","volume":"272","author":"M MacFarlane","year":"1997","unstructured":"MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272:25417","journal-title":"J Biol Chem"},{"key":"370_CR32","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","volume":"21","author":"M MacFarlane","year":"2002","unstructured":"MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809","journal-title":"Oncogene"},{"key":"370_CR33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00062752-200207000-00010","volume":"9","author":"A Melnick","year":"2002","unstructured":"Melnick A, Licht JD (2002) Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9:322","journal-title":"Curr Opin Hematol"},{"key":"370_CR34","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M000482200","volume":"275","author":"F Muhlenbeck","year":"2000","unstructured":"Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J, Wajant H (2000) The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 275:32208","journal-title":"J Biol Chem"},{"key":"370_CR35","first-page":"2599","volume":"4","author":"PS Multani","year":"1998","unstructured":"Multani PS, O\u2019Day S, Nadler LM, Grossbard ML (1998) Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res 4:2599","journal-title":"Clin Cancer Res"},{"key":"370_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271","journal-title":"J Immunol Methods"},{"key":"370_CR37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","volume":"277","author":"G Pan","year":"1997","unstructured":"Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815","journal-title":"Science"},{"key":"370_CR38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","volume":"276","author":"G Pan","year":"1997","unstructured":"Pan G, O\u2019Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111","journal-title":"Science"},{"key":"370_CR39","first-page":"2848","volume":"62","author":"M Peipp","year":"2002","unstructured":"Peipp M, Kupers H, Saul D, Schlierf B, Greil J, Zunino SJ, Gramatzki M, Fey GH (2002) A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 62:2848","journal-title":"Cancer Res"},{"key":"370_CR40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-1759(01)00298-8","volume":"251","author":"M Peipp","year":"2001","unstructured":"Peipp M, Simon N, Loichinger A, Baum W, Mahr K, Zunino SJ, Fey GH (2001) An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells. J Immunol Methods 251:161","journal-title":"J Immunol Methods"},{"key":"370_CR41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01788960","volume":"41","author":"GA Pietersz","year":"1995","unstructured":"Pietersz GA, Wenjun L, Sutton VR, Burgess J, McKenzie IF, Zola H, Trapani JA (1995) In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody. Cancer Immunol Immunother 41:53","journal-title":"Cancer Immunol Immunother"},{"key":"370_CR42","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687","journal-title":"J Biol Chem"},{"key":"370_CR43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","volume":"351","author":"LZ Rassenti","year":"2004","unstructured":"Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893","journal-title":"N Engl J Med"},{"key":"370_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","volume":"33","author":"S Sakajiri","year":"2005","unstructured":"Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33:53","journal-title":"Exp Hematol"},{"key":"370_CR45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"RH Scheuermann","year":"1995","unstructured":"Scheuermann RH, Racila E (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 18:385","journal-title":"Leuk Lymphoma"},{"key":"370_CR46","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.168.3.1205","volume":"168","author":"I Stamenkovic","year":"1988","unstructured":"Stamenkovic I, Seed B (1988) CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 168:1205","journal-title":"J Exp Med"},{"key":"370_CR47","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188","volume":"88","author":"MJ Stone","year":"1996","unstructured":"Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188","journal-title":"Blood"},{"key":"370_CR48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00262-005-0081-y","volume":"55","author":"K Tamada","year":"2006","unstructured":"Tamada K, Chen L (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55:355","journal-title":"Cancer Immunol Immunother"},{"key":"370_CR49","doi-asserted-by":"crossref","first-page":"23319","DOI":"10.1074\/jbc.M910438199","volume":"275","author":"A Truneh","year":"2000","unstructured":"Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML (2000) Temperature-sensitive differential affinity of TRAIL for its receptors DR5 is the highest affinity receptor. J Biol Chem 275:23319","journal-title":"J Biol Chem"},{"key":"370_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","volume":"71","author":"FM Uckun","year":"1988","unstructured":"Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71:13","journal-title":"Blood"},{"key":"370_CR51","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1038\/sj.onc.1204558","volume":"20","author":"H Wajant","year":"2001","unstructured":"Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20:4101","journal-title":"Oncogene"},{"key":"370_CR52","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","volume":"16","author":"H Walczak","year":"1997","unstructured":"Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 16:5386","journal-title":"Embo J"},{"key":"370_CR53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157","journal-title":"Nat Med"},{"key":"370_CR54","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628","journal-title":"Oncogene"},{"key":"370_CR55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673","journal-title":"Immunity"},{"key":"370_CR56","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.0505539102","volume":"102","author":"N Yazawa","year":"2005","unstructured":"Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 102:15178","journal-title":"Proc Natl Acad Sci USA"},{"key":"370_CR57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1593\/neo.05823","volume":"8","author":"MF Ziauddin","year":"2006","unstructured":"Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM, Tsai W, Cole GW Jr Schrump DS, Nguyen DM (2006) Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L\/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8:446","journal-title":"Neoplasia"},{"key":"370_CR58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.09.001","volume":"240","author":"SJ Zunino","year":"2006","unstructured":"Zunino SJ, Storms DH (2006) Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett 240:123","journal-title":"Cancer Lett"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-007-0370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0370-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:27:04Z","timestamp":1737332824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-007-0370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s00262-007-0370-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,31]]}}}